Participated in Anaheim Bio's oversubscribed EUR 40M Series A to take ANA1 into the clinic.
NOV 5, 2026
Dutch biotech developing small-molecule therapeutics
Dutch biotech developing small-molecule therapeutics. Its lead candidate ANA-1 is designed to lower extracellular pyrophosphate (PPi) and limit calcium pyrophosphate crystal formation in calcium pyrophosphate deposition disease (CPPD, or pseudogout), an underserved form of inflammatory arthritis. ANA-1 is preclinical and expected to enter Phase I testing in 2027.